Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Ngl Fine Chem
Join Channel
Consolidated Standalone

NGL Fine-Chem

₹2040.1 -7.5 | 0.4%

Market Cap ₹1260 Cr.

Stock P/E 30.5

P/B 4.7

Current Price ₹2040.1

Book Value ₹ 438.1

Face Value 5

52W High ₹2822.5

Dividend Yield 0.09%

52W Low ₹ 1728.6

Edit Ratio

NGL Fine-Chem Research see more...

Stocx User

NGL Fine Chem Ltd

Overview Inc. Year: 1981Industry: Pharmaceuticals & Drugs

NGL Fine-Chem Ltd is engaged in pharmaceutical commercial enterprise. The Company is a producer of prescription drugs and intermediates for utilization in veterinary and human health. Its merchandise consist of Active Pharmaceutical Ingredients (APIs) animal health, APIs human health, Intermediates and finished dosage form categories. The APIs animal health products encompass Homidium Chloride, Clorsulon, Parvaquone, Carprofen, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Amitraz, Praziquantel, Flunixin Meglumine, S-Methoprene, Imidocarb Dipropionate and Nitroxynil. The APIs human health merchandise encompass Nitazoxanide, Atovaquone, Febuxostat and Ranolazine. The Intermediates products consist of 4 Aminobenzamidine Dihydrochloride, 3-Aminobenzamidine Dihydrochloride, Aceturic Acid and 3-Trichlorovinyl Aniline Hydrochloride. The Finished dosage form products consist of Diminazene Aceturate Granules and Homidium Chloride Tablets. The Company has production plants positioned in Mumbai.

Read More..

NGL Fine-Chem Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

NGL Fine-Chem Quarterly Results

#(Fig in Cr.) Mar 2017 Jun 2017 Sep 2017 Dec 2017 Mar 2018
Net Sales 26 23 29 29 32
Other Income 1 1 1 2 1
Total Income 27 24 30 31 33
Total Expenditure 21 21 23 24 26
Operating Profit 6 3 7 7 7
Interest 0 0 0 1 1
Depreciation 1 1 2 1 1
Exceptional Income / Expenses 0 0 0 0 0
Profit Before Tax 5 2 5 6 4
Provision for Tax 2 1 2 2 1
Profit After Tax 3 2 3 4 3
Adjustments -3 -2 -3 -4 -3
Profit After Adjustments 0 0 0 0 0
Adjusted Earnings Per Share 5.6 2.6 5.6 6.8 5

NGL Fine-Chem Profit & Loss

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
Net Sales 79 88 96 100 114 153 152 258 319 275 329 113
Other Income 0 0 0 1 3 4 3 9 13 8 16 5
Total Income 79 88 96 101 116 157 156 267 331 283 345 118
Total Expenditure 68 73 74 74 92 121 131 181 253 246 284 94
Operating Profit 11 15 22 27 24 36 24 86 79 36 61 24
Interest 2 2 2 1 2 3 3 2 2 2 2 2
Depreciation 2 3 3 3 5 6 7 7 8 8 8 5
Exceptional Income / Expenses -1 2 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 7 13 18 23 18 28 14 76 69 27 51 17
Provision for Tax 2 5 6 8 5 7 4 21 17 6 12 6
Profit After Tax 5 8 11 15 13 20 11 55 52 20 39 12
Adjustments 0 0 0 0 0 0 -0 -0 -0 -0 -0 -12
Profit After Adjustments 5 8 11 15 13 20 10 55 52 20 38 0
Adjusted Earnings Per Share 7.3 13.5 18.4 24.1 20.4 32.6 17.2 89.8 84.6 32.6 62.3 20

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 20% 8% 17% 15%
Operating Profit CAGR 69% -11% 11% 19%
PAT CAGR 95% -11% 14% 23%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 8% -7% 37% 38%
ROE Average 16% 18% 22% 24%
ROCE Average 19% 22% 26% 28%

NGL Fine-Chem Balance Sheet

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Shareholder's Funds 25 33 44 59 72 92 101 155 207 226 263
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 3 2 0 9 12 8 8 6 3 2 1
Other Non-Current Liabilities 1 1 1 3 4 4 3 5 5 4 5
Total Current Liabilities 27 31 32 39 44 45 43 39 63 57 84
Total Liabilities 56 67 78 111 133 149 156 206 278 288 353
Fixed Assets 19 17 24 25 56 61 61 58 59 59 60
Other Non-Current Assets 2 5 4 27 17 2 12 25 49 69 89
Total Current Assets 35 44 50 59 60 86 83 123 170 159 204
Total Assets 56 67 78 111 133 149 156 206 278 288 353

NGL Fine-Chem Cash Flow

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Opening Cash & Cash Equivalents 2 1 2 0 0 1 1 0 2 1 8
Cash Flow from Operating Activities -0 8 8 10 22 9 20 27 16 32 11
Cash Flow from Investing Activities -4 -3 -10 -10 -21 -10 -19 -24 -16 -24 -17
Cash Flow from Financing Activities 3 -4 2 0 0 0 -1 -1 -1 -1 -1
Net Cash Inflow / Outflow -1 1 0 -0 1 -1 -0 2 -1 7 -7
Closing Cash & Cash Equivalent 1 2 2 0 1 1 0 2 1 8 0

NGL Fine-Chem Ratios

# Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Earnings Per Share (Rs) 7.33 13.48 18.45 24.09 20.45 32.58 17.16 89.79 84.57 32.57 62.35
CEPS(Rs) 11.08 17.69 22.86 29.08 27.83 42.78 28.92 101.75 96.99 45.35 75.54
DPS(Rs) 0 0 0 0 0 1.75 1.75 1.75 1.75 1.75 1.75
Book NAV/Share(Rs) 39.73 53.12 71.57 96.16 116.61 149.11 163.81 251.62 334.36 365.04 425.39
Core EBITDA Margin(%) 13.22 15.58 21.19 23.93 18.64 21.08 13.74 29.84 20.69 10.44 13.61
EBIT Margin(%) 9.75 15.01 18.76 22.37 16.96 19.66 11.16 30.29 22.24 10.34 15.96
Pre Tax Margin(%) 7.89 13.4 17.24 21.43 15.44 18 9.43 29.44 21.64 9.67 15.41
PAT Margin (%) 5.32 8.68 11 13.98 10.92 13.14 6.97 21.48 16.4 7.31 11.71
Cash Profit Margin (%) 8.05 11.38 13.63 16.87 14.86 17.25 11.74 24.35 18.8 10.19 14.19
ROA(%) 8.77 13.62 15.83 15.79 10.34 14.25 6.96 30.7 21.61 7.11 12.02
ROE(%) 20.33 29.04 29.59 28.73 19.22 24.52 10.97 43.22 28.86 9.31 15.78
ROCE(%) 22.24 33.03 37.14 33.8 21.68 27.63 13.65 51.9 34.71 11.5 18.93
Receivable days 83.6 94.6 102.87 107.26 91.18 72.43 71.13 45.06 58.68 86.31 82.28
Inventory Days 39.42 39.2 38.99 37.42 45.16 42.2 55.77 46.47 53.25 54.46 38.59
Payable days 101.85 119.13 122.54 123.18 145.27 110.66 97.43 73.54 65.49 70.5 82.87
PER(x) 3.37 5.35 12.26 15.93 20.08 14.42 14.76 17.07 23.15 36.75 33.52
Price/Book(x) 0.62 1.36 3.16 3.99 3.52 3.15 1.55 6.09 5.86 3.28 4.91
Dividend Yield(%) 0 0 0 0 0 0.37 0.69 0.11 0.09 0.15 0.08
EV/Net Sales(x) 0.4 0.63 1.58 2.59 2.43 2.05 1.19 3.71 3.89 2.76 4.02
EV/Core EBITDA(x) 2.76 3.7 6.86 9.59 11.44 8.63 7.49 11.2 15.77 20.89 21.82
Net Sales Growth(%) 41.93 11.99 9.02 3.56 13.97 34.77 -0.65 69.65 23.43 -13.69 19.6
EBIT Growth(%) 42.79 73.76 34.89 22.54 -17.61 53.47 -43.63 360.65 -9.35 -59.9 84.73
PAT Growth(%) 55.66 83.95 36.83 30.6 -15.14 59.33 -47.32 423.12 -5.81 -61.49 91.46
EPS Growth(%) 55.66 83.95 36.83 30.6 -15.14 59.33 -47.32 423.12 -5.81 -61.49 91.46
Debt/Equity(x) 0.68 0.4 0.33 0.38 0.37 0.29 0.28 0.11 0.15 0.14 0.13
Current Ratio(x) 1.33 1.42 1.57 1.52 1.35 1.91 1.93 3.15 2.69 2.81 2.41
Quick Ratio(x) 1.01 1.03 1.25 1.22 0.97 1.5 1.28 2.18 1.82 2.33 1.91
Interest Cover(x) 5.24 9.3 12.39 23.73 11.11 11.82 6.47 35.49 37.07 15.55 29.1
Total Debt/Mcap(x) 1.09 0.3 0.1 0.1 0.11 0.09 0.18 0.02 0.02 0.04 0.03

NGL Fine-Chem Shareholding Pattern

# Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Promoter 73.81 73.81 73.81 73.53 73.53 73.06 73.06 72.74 72.74 72.74
FII 0.05 0.05 0 0 0 0.02 0.04 0.1 0.03 0.02
DII 0 0 0 0 0.01 0 0 0 0 0
Public 26.14 26.14 26.19 26.47 26.46 26.92 26.9 27.16 27.23 27.25
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Debtor days have increased from 70.5 to 82.87days.
  • Stock is trading at 4.7 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

NGL Fine-Chem News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!